JPRN-UMIN000018376
Completed
未知
Efficacy and safety of rituximab for patients with severe rheumatic disease - Efficacy and safety of rituximab for patients with severe rheumatic disease
Yokohama City University Hospital Department of Pediatrics0 sites20 target enrollmentJuly 22, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Childhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren'
- Sponsor
- Yokohama City University Hospital Department of Pediatrics
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Pulmonary tuberculosis, active bacterial infection or deep mycotic infection 2\. Infection of HIV, HCV or HBV 3\. Administraion of live vaccine within 4 weeks 4\. Interstatial lung disease 5\. Cardiac dysfunction 6\. Pregnant subjects or subjects who do not agree with contraception during the study period
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTRheumatoid arthritisMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300
Recruiting
Phase 2
Safety and Efficacy of Rituximab in patients with juvenile dermatomyositisJuvenile dermatomyositis.Juvenile dermatomyositisM33.0IRCT20231119060108N1Shahid Beheshti University of Medical Sciences7
Active, not recruiting
Phase 1
Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitisEUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106
Active, not recruiting
Not Applicable
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
Completed
Not Applicable
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndromeJPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10